MME and prostate cancer: This finding is well reflected in the favorable increase in tumor-to-kidney ratios from 2.9 (in controls) to 4.1 (in the Entresto® group), highlighting the advantageous application of the [99mTc]Tc-DB7+[99mTc]Tc-DT11 cocktail during in situ NEP inhibition in targeting the prostate cancer lesions.